The FDA approved Merck’s Keytruda for the treatment of stage IB, II or IIIA non-small cell lung cancer after resection or platinum-based chemotherapy.

Through ongoing collaboration, new companion diagnostic aims to deliver next-generation sequencing results in as little as 24 hours to help advance precision oncology.

Junshi Biosciences’ Neotorch is the world’s first registered Phase III immuno-oncology trial for lung cancer to post positive EFS (event-free survival) data.

Exelixis’ cancer portfolio stumbled Thursday as the Alameda, CA-based company reported that a Phase III study of cabozantinib in combination with Roche’s Tecentriq (atezolizumab) failed to hit the primary endpoint of overall survival in second-line non-small cell lung cancer.

The FDA greenlit Libtayo plus chemotherapy to treat patients with advanced NSCLC irrespective of EGFR, ALK or ROS1 aberrations. It is the drug’s second approval in this space.

Novartis’ positive-third quarter growth report Tuesday was marred slightly by several clinical setbacks that resulted in the termination of studies in liver transplant and non-small cell lung cancer. 

GSK reported Wednesday its checkpoint inhibitor Jemperli yielded positive data in non-small cell lung cancer, moving the monoclonal antibody potentially closer to the market in this indication.